8月21日，吉利德科学宣布以3.5亿美元全资收购CAR-T疗法开发公司Interius ...

圣莫尼卡/费城 - 吉利德科学公司 (NASDAQ: GILD )旗下的Kite公司，作为生物技术行业的重要参与者，市值达1478亿美元，周三宣布已达成最终协议，将以3.5亿美元现金收购私人持有的Interius ...

当下，随着吉利德的入局，体内CAR-T领域的“多国杀”格局初定，巨头的军备竞赛已进入白热化。这场竞赛的背后，不仅是对下一代技术制高点的争夺，更是对细胞治疗未来形态的定义权之争。

所以对于各IN VIVO CAR-T平台/公司的评估，评估其载体特点及后续的转染、表达、安全性等参数是重中之重。目前主流的载体分为病毒载体和非病毒载体，后续我将根据载体及代表公司，做个系列的文章来梳理。今天重点来讨论一下病毒载体，特别是慢病毒载体。

The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Interius Bio基因治疗服务商，专注于血液系统恶性肿瘤，为用户提供癌症基因治疗及细胞免疫解决方案。近日，Kite以3.5亿美元收购Interius Bio。

Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

格隆汇8月21日｜吉利德科学旗下的KitePharma表示，将以3.5亿美元现金收购私人控股的生物技术公司Interius BioTherapeutics，以推进CAR-T细胞癌症疗法的发展。

A University of Pennsylvania spinout that is developing a faster and cheaper way to modify immune cells to fight cancer will be sold to a unit of Gilead Sciences Inc. for $350 million under an ...